22/10/2018 – Final results will be available in 2019. Post navigationPreviousPrevious post:Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral SclerosisNextNext post:PatientsRelated PostsUpdate on the restructuring of the AB Science clinical development department in 201819 December 2018Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018First half of 2018 revenues1 October 2018Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer23 July 2018Results of the Combined General Shareholders’ Meeting held on June 29 20183 July 2018Combined General Shareholders’ Meeting held on June 29, 20183 July 2018
Update on the restructuring of the AB Science clinical development department in 201819 December 2018
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer23 July 2018
